Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy InflaRx N-V stock | $2.47

Learn how to easily invest in InflaRx N-V stock.

InflaRx N.V is a biotechnology business based in the US. InflaRx N-V shares (IFRX) are listed on the NASDAQ and all prices are listed in US Dollars. InflaRx N-V employs 47 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in InflaRx N-V

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – IFRX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

InflaRx N-V stock price (NASDAQ: IFRX)

Use our graph to track the performance of IFRX stocks over time.

InflaRx N-V shares at a glance

Information last updated 2021-10-11.
Latest market close$2.47
52-week range$2.23 - $6.38
50-day moving average $2.63
200-day moving average $2.98
Wall St. target price$8.23
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.27

Buy InflaRx N-V shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy InflaRx N-V stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

InflaRx N-V price performance over time

Historical closes compared with the close of $2.47 from 2021-10-15

1 week (2021-10-08) -8.18%
1 month (2021-09-16) -7.49%
3 months (2021-07-16) -5.36%
6 months (2021-04-16) -33.24%
1 year (2020-10-16) -50.99%
2 years (2019-10-16) 4.22%
3 years (2018-10-16) 34.85
5 years (2016-10-12) N/A

InflaRx N-V financials

Gross profit TTM $0
Return on assets TTM -19.09%
Return on equity TTM -34.11%
Profit margin 0%
Book value $2.80
Market capitalisation $118.9 million

TTM: trailing 12 months

Shorting InflaRx N-V shares

There are currently 364,518 InflaRx N-V shares held short by investors – that's known as InflaRx N-V's "short interest". This figure is 212.1% up from 116,795 last month.

There are a few different ways that this level of interest in shorting InflaRx N-V shares can be evaluated.

InflaRx N-V's "short interest ratio" (SIR)

InflaRx N-V's "short interest ratio" (SIR) is the quantity of InflaRx N-V shares currently shorted divided by the average quantity of InflaRx N-V shares traded daily (recently around 450022.22222222). InflaRx N-V's SIR currently stands at 0.81. In other words for every 100,000 InflaRx N-V shares traded daily on the market, roughly 810 shares are currently held short.

However InflaRx N-V's short interest can also be evaluated against the total number of InflaRx N-V shares, or, against the total number of tradable InflaRx N-V shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case InflaRx N-V's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 InflaRx N-V shares in existence, roughly 10 shares are currently held short) or 0.0106% of the tradable shares (for every 100,000 tradable InflaRx N-V shares, roughly 11 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against InflaRx N-V.

Find out more about how you can short InflaRx N-V stock.

InflaRx N-V share dividends

We're not expecting InflaRx N-V to pay a dividend over the next 12 months.

InflaRx N-V share price volatility

Over the last 12 months, InflaRx N-V's shares have ranged in value from as little as $2.23 up to $6.38. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while InflaRx N-V's is 0.4402. This would suggest that InflaRx N-V's shares are less volatile than average (for this exchange).

InflaRx N-V overview

InflaRx N. V. , a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the Germany and United States. Its C5a is an inflammatory mediator that is involved in the enhancement of a variety of autoimmune and other inflammatory diseases. The company's lead product candidate is IFX-1, an intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase IIb clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; to treat ANCA-associated vasculitis, a rare and life-threatening autoimmune disease; and for the treatment of pyoderma gangrenosum, a chronic inflammatory skin disorder, as well as developing IFX-1 for the treatment of oncological diseases. It also develops IFX-2 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. InflaRx N.

Frequently asked questions

What percentage of InflaRx N-V is owned by insiders or institutions?
Currently 14.886% of InflaRx N-V shares are held by insiders and 25.708% by institutions.
How many people work for InflaRx N-V?
Latest data suggests 47 work at InflaRx N-V.
When does the fiscal year end for InflaRx N-V?
InflaRx N-V's fiscal year ends in December.
Where is InflaRx N-V based?
InflaRx N-V's address is: Winzerlaer Str. 2, Jena, Germany, 07745
What is InflaRx N-V's ISIN number?
InflaRx N-V's international securities identification number is: NL0012661870
What is InflaRx N-V's CUSIP number?
InflaRx N-V's Committee on Uniform Securities Identification Procedures number is: N44821101

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site